Liquidmetal® Technologies, Inc. is the foremost developer of bulk alloys, which utilize the performance advantages that amorphous alloy technology provides. Amorphous alloys are unique materials distinguished by their ability to retain a random structure when they solidify. This is in comparison to the crystalline atomic structure that forms in ordinary metals and alloys. Liquidmetal® Technologies has its headquarters in Rancho Santa Margarita, California, where it also has its Manufacturing Center of Excellence. The Company’s shares trade on the OTC Markets.

Liquidmetal Technologies is the first company to produce amorphous alloys in commercially viable bulk form. This is enabling critical improvements in products across a wide array of industries.

Liquidmetal has two to three times the strength of titanium and stainless steel. It undergoes processing alike to plastics on the Company's proprietary Liquidmetal molding machines. The Company’s class of patented alloys and processes form the foundation of high performance materials used in a broad spectrum of medical, military, consumer, and industrial, and sporting goods products.

Liquidmetal is processed and solidified in a vitreous or amorphous state (frozen liquid). Liquidmetal® Technologies’ alloys are, in many cases, stronger, harder, more elastic, and more wear and corrosion resistant than typically used high-performance alloys.

The Company’s "bulk" amorphous alloys possess advantages normally associated with plastics. These include the ability to undergo molding into precision, complex, as well as highly finished products. Liquidmetal® Technologies controls the Intellectual Property (IP) rights with greater than 70 U.S. patents.

Liquidmetal® Technologies and the University of Southern California’s M.C. Gill Composites Center are working in tandem to develop an advanced manufacturing process to produce large-scale amorphous metal and fiber laminate sheets for space applications. The work is funded by a NASA SBIR (Small Business Innovation Research) Phase I contract addressing solicitation topic number Z2.01, “Cross cutting advanced manufacturing process for large scale bulk metallic glass systems for aerospace applications.”

Professor Lugee Li, Chairman and Chief Executive Officer at Liquidmetal® Technologies was presented with an Excellence Award from the International Magnesium Association (IMA) at the 2017 World Magnesium Conference, which took place in Singapore on May 21-23, 2017. This Excellence Award was presented to Professor Li in recognition of a new automotive cast design for structural portions of automotive closure panels (side doors, lift gates, hoods, trunk lids) where his innovative, novel, and creative design and development of magnesium demonstrated considerable advances over existing practice.

In Q2 2017, ended June 30, 2017, Liquidmetal® Technologies received two hot crucible amorphous metal molding machines from its licensing partner Eontec Ltd. The machines permit the production of amorphous alloy parts, which are up to three times larger and one-third the cost of established technologies. The Company also continued the build out of its new manufacturing facility in Q2, which it bought in February of this year.

Liquidmetal Technologies, Inc. (LQMT), closed Friday's trading session at $0.123, up 6.96%, on 612,112 volume with 77 trades. The average volume for the last 3 months is 1,153,204 and the stock's 52-week low/high is $0.100/$0.287.

Golden Arrow Resources Corp. is an explorer and prospect generator. Its emphasis is on identifying, acquiring, and advancing precious and base metal discoveries with the goal of defining first-class deposits. The Company’s primary focus is on advancing its flagship Chinchillas Silver Project in Jujuy Province, Argentina.

Golden Arrow is actively exploring a new portfolio of advanced projects in Chile, and also other targets within its portfolio of greater than 200,000 hectares of properties in Argentina. Golden Arrow Resources is a member of the Grosso Group; a management company specializing in resource exploration. OTCQB-listed, Golden Arrow Resources has exploration offices in Ciudad de Mendoza, Argentina.

Golden Arrow’s other Argentina projects include the Antofalla Silver-Gold-Base Metal Project in Catamarca Province; and the Don Bosco Copper-Gold Project and the Caballos Copper-Gold Project, both in La Rioja Province.

Furthermore, projects include the Mogote Copper-Gold Project; the Pescado Gold Project; and the Frontera District - Potrerillos Gold-Silver Project. All of these projects are in San Juan Province.

The Chinchillas Silver deposit will be developed into a satellite open-pit mine. The Chinchillas Silver Project features low capex (capital expenditure) and fast-tracked development using infrastructure from the Pirquitas mine. It has a positive pre-feasibility study with strong economics and immediate production income from the Pirquitas mine operation.

Golden Arrow Resources formed a Joint Venture (JV) with Silver Standard Resources, Inc. The JV is called Puna Operations, Inc. (POI). It wasformed to hold the Chinchillas project and the Pirquitas project, which comprises the San Miguel open pit mine that ended mining operations in January 2017 (the Pirquitas Pit), and the associated mineral processing facilities and tailings facility (the Pirquitas Operation) in Argentina. POI is 75 percent owned and operated by Silver Standard and owned 25 percent by Golden Arrow Resources.

Moreover, Golden Arrow Resources has created a 100 percent owned subsidiary called “New Golden Explorations, Inc.” New Golden Explorations has been centered on acquiring advanced stage exploration projects with the potential to deliver sizable added share value. New Golden Explorations earlier announced the acquisition of the Indiana Gold-Copper and the Atlantida Copper-Gold projects.

In December, Golden Arrow Resources announced that its JV partner in Puna Operations declared commercial production at the Chinchillas silver-zinc-lead mine as of December 1, 2018.

Golden Arrow Resources Corp. (GARWF), closed Friday's trading session at $0.2669, up 2.30%, on 189,568 volume with 38 trades. The average volume for the last 3 months is 130,095 and the stock's 52-week low/high is $0.169/$0.58.

BioSig Technologies, Inc. is a medical device company developing PURE EP™. This is a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures. BioSig is preparing to commercialize the PURE EP™ System. The PURE EP™ is a next-generation surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system. BioSig Technologies has its office in Los Angeles, California centered on research and development (R&D).

The design of the PURE EP™ System is to help electrophysiologists in making clinical decisions in real-time through acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data, which may be used to guide the electrophysiologists in identifying ablation targets (areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia)).

BioSig has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center. The Company has performed pre-clinical studies at the Mayo Clinic in Minnesota. BioSig Technologies is also collaborating with other prestigious cardiac arrhythmia centers. The Company has also expressed its plan to enter the developing field of bioelectric medicine. In addition, it has partnered with Minnetronix on technology development.

Last month, BioSig Technologies announced that it signed an agreement with Mayo Clinic to conduct First-in-Human studies using the PURE EP™ System. The First-in-Human studies are directed at validating the safety and efficacy of the PURE EP™ System during mapping and ablation procedures in the cardiac EP lab. Mayo Clinic has conducted twelve pre-clinical studies to date using the PURE EP™ System, results of which have been published in several journals.

Mayo Clinic becomes the second center to launch pilot First-in-Human studies ahead of the Company’s targeted commercial launch of its first product, PURE EP™ System this year. BioSig announced on November 28, 2018 that it begins installations of the first systems at Texas Cardiac Arrhythmia Institute in Austin, Texas. BioSig Technologies signed a 10-year collaboration agreement with Mayo Clinic in March of 2017.

BioSig Technologies, Inc. (BSGM), closed Friday's trading session at $4.38, down 1.57%, on 16,277 volume with 85 trades. The average volume for the last 3 months is 55,011 and the stock's 52-week low/high is $3.213/$7.875.

International Stem Cell Corp. is a clinical stage biotechnology company headquartered in Carlsbad, California. It is developing stem cell-based therapies and biomedical products. The Company’s focus is on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. International Stem Cell has a research facility in Oceanside, California.

The Company’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). The hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. They offer the potential to create the first true stem cell bank, UniStemCell™.

The UniStemCell™ bank is the life science industry’s first collection of non-embryonic histocompatible human stem cells available for research and commercial use. The human leukocyte antigen (HLA) system represents antigens vital for transplantation.

International Stem Cell scientists have created the first parthenogenetic, homozygous stem cell line. The Company produces and markets specialized cells and growth media for therapeutic research around the world through its subsidiary Lifeline Cell Technology and stem cell-based skin care products through its subsidiary Lifeline Skin Care.

This past November, International Stem Cell announced positive 12-month results of the first cohort and six-month interim results of the second cohort of its presently-ongoing, single-arm, open-label phase 1 clinical study (NCT02452723) evaluating the safety and tolerability of its lead candidate, ISC-hpNSC®, a cellular therapeutic comprising human parthenogenetic neural stem cells, for the treatment of Parkinson’s disease (PD).

Six of the 12 patients in the clinical trial completed one year of follow-up observations. One patient in the low dose cohort has now been followed for 2 years. There have been no safety signals or serious adverse effects seen to date as related to the transplanted ISC-hpNSC® cells.

The evaluation is based on greater than 12 months of safety data from the first cohort (low dose), and 6 months of data from the second cohort (mid dose). Each cohort consists of 4 patients. Dosing of patients in Cohort 3, which is receiving the highest dose, is ongoing.

International Stem Cell Corp. (ISCO), closed Friday's trading session at $1.55, up 3.33%, on 842 volume with 8 trades. The average volume for the last 3 months is 4,477 and the stock's 52-week low/high is $1.25/$1.77.

BAB, Inc. (BABB)

Zacks, Greenbackers, Marketbeat.com, OTC Markets Group, and SmallCapVoice reported on BAB, Inc. (BABB), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

BAB, Inc. franchises and licenses Big Apple Bagels®, My Favorite Muffin®, SweetDuet® frozen yogurt and Brewsters’® Coffee. In addition, BAB engages in the sale of bagels, muffins, and coffee by way of nontraditional channels of distribution, including under licensing agreements. BAB is headquartered in Deerfield, Illinois. BAB Systems, Inc., is the Company’s franchising subsidiary.

For Q2 ended May 31, 2017. BAB had Revenues of $608,000 and Net Income of $136,000, or $0.02 per share. This is in comparison to Revenues of $564,000 and Net Income of $132,000, or $0.02 per share, for the same quarter in 2016.

The Company’s Big Apple Bagels is a national chain of fast-casual restaurants. BAB’s My Favorite Muffin is a national chain of fast-casual restaurants with hand-crafted products. BAB’s SweetDuet® is a Duet Yourself® frozen yogurt bar. It includes a full offering of gourmet muffins.

BAB acquires its revenues primarily from the continuing royalties paid to it by its franchisees and receipt of initial franchise fees. Also, the Company receives revenue from the sale of licensed products (My Favorite Muffin mix, Big Apple Bagels cream cheese, Big Apple Bagels frozen bagels, and Brewster's coffee).

Royalty fees represent a 5 percent fee on net retail and wholesale sales of franchised units. BAB earns a licensing fee from the sale of BAB branded products from a third-party commercial bakery, to the franchised and licensed units. Bab’s nontraditional channels of distribution are Kohr Bros. and Green Beans Coffee. Additionally, included in licensing fees and other income is Operation's Sign Shop revenue. The Sign Shop provides the majority of signage. This includes but is not limited to, posters, menu panels, outside window stickers, and counter signs to franchisees to provide consistency and convenience.

BAB’s Brewsters' Coffee® hand picks only the top 2-3 percent of Arabica beans from around the world. Brewsters’ hand roasts its beans in small batches. Moreover, BAB’s has Jacobs Bros. Bagels (frozen raw dough and par-baked varieties).

BAB Systems has opened a new My Favorite Muffin, Your All Day Bakery Café®, at 11211 Lee Highway, in Fairfax, Virginia. The new Fairfax franchise is owned and operated by Two Moms Café, LLC.

This past April, BAB Systems, the franchising subsidiary of BAB, announced the opening of its newest Big Apple Bagels. The restaurant is situated at 5410 Yellowstone Road, in Cheyenne, Wyoming. The new unit is BAB’s first in Wyoming.

Furthermore, BAB Systems and Mont Royal General Trading LLC, now known as Mont Royal Restaurant and Café, LLC announced that they terminated the 2014 Master Franchise Development Agreement for the development of Big Apple Bagels stores across the Middle East. They entered into a new exclusive licensing agreement for the development of Big Apple Bagels Cafés within the United Arab Emirates (UAE). This new agreement will apply only to the UAE.

Also, BAB Systems recently announced the opening of its newest Big Apple Bagels, located in Fishers, Indiana. The restaurant is in Geist Landing, at 11675 Olio Road. The new unit is BAB’s second restaurant in the town of Fishers.

BAB, Inc. (BABB), closed Friday's trading session at $0.68, up 4.45%, on 400 volume with 1 trade. The average volume for the last 3 months is 5,556 and the stock's 52-week low/high is $0.61/$0.74.

MYnd Analytics, Inc. is a market leader in reducing costs and improving the delivery of mental health services through the combination of telemedicine and data analytics/artificial (augmented) intelligence. MYnd brings objective physical findings to psychiatric treatment to reduce trial and error treatment in mental health. The Company provides an innovative set of reference data and analytic tools for clinicians and researchers in psychiatry. A predictive medicine company, MYnd Analytics is based in Mission Viejo, California.

MYnd Analytics continues to integrate its earlier acquired Arcadian Telepsychiatry Services LLC business into its legacy business. MYnd Analytics earlier announced that its wholly-owned subsidiary, Arcadian Telepsychiatry Services launched a new program to offer, via its network of Providers, youths in rural, suburban and urban markets with school-based access to telepsychiatry, teletherapy and other mental health services.

Telepsychiatry involves the use of video conferencing equipment to conduct real time mental health consultations between a clinician and a patient. The design of the program is to benefit children and teenagers throughout the nation, especially those with limited access to mental health services.

MYnd has its Psychiatric EEG Evaluation Registry, or PEER Online®. The aim of PEER Online is to provide objective, personalized data to help physicians in the selection of suitable medications. PEER Online is a cloud-based platform. It is a registry and reporting platform. PEER Online enables medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG).

The Company also has its MYnd Analytics Center. The Center provides a convenient, relaxing, and welcoming environment for one to receive their EEG and PEER Report™. The EEG is performed on-site at the MYnd Analytics Center. Physicians who use PEER lessen trial and error re-scribing.

Recently, MYnd Analytics announced that it was awarded a subcontract to incorporate its PEER report within a project to develop a suicide prevention toolkit, for the U.S. Department of Health and Human Services (HHS).

Mr. George Carpenter, Chief Executive Officer of MYnd Analytics, stated, “We are honored to be a part of this important project, which involves development of a suicide prevention tool kit for HHS. Importantly, we look forward to leveraging our expertise and the extensive data we have compiled through the PEER registry... Multiple studies — including two of our own — have shown a relationship between EEG findings, medication response, and suicidality. We look forward to leveraging this powerful data as part of this new HHS sponsored program.”

MYnd Analytics, Inc. (MYND), closed Friday's trading session at $0.7501, up 5.51%, on 68,913 volume with 79 trades. The average volume for the last 3 months is 191,003 and the stock's 52-week low/high is $0.62/$4.08.

Osprey Gold Development Ltd. concentrates on exploring five historically producing gold properties in the Province of Nova Scotia. Its flagship project is Goldenville, positioned in the historical mining district Goldenville, which is one of eastern Canada’s most significant gold belts. Osprey Gold has the option to earn 100 percent (subject to certain royalties) in all five properties. This includes the Goldenville Gold Project. OTCQB-listed, Osprey Gold Development has its corporate office in Vancouver, British Columbia.

The Goldenville Gold Project has an updated NI 43-101 inferred resource that includes 2,800,000 tonnes at 3.20 g/t gold for a total of 288,000 ounces of gold (2.8 mil tonnes at 4.96 g/t gold for 447,000 ounces of gold uncapped). Osprey Gold Development is also exploring the past producing Lower Seal Harbour, Miller Lake, Caribou, and Gold Lake gold projects.

The Company entered into a definitive agreement wherein it acquired an option to acquire the Caribou Gold Property from John Logan Enterprises Ltd. With this Option Agreement, Osprey Gold may acquire a 100 percent interest (subject to certain royalties) in 16 contiguous mining claims (256 hectares) hosting the past-producing Caribou Property.

The Lower Seal Harbour project is in Guysborough County, Nova Scotia. The property is roughly 35 kilometers from Goldenville. Gold at Lower Seal Harbour is found in the veins and the host rocks.

The Caribou Gold property is 80 kilometers northwest of Halifax, Nova Scotia and 10 kilometers south of the rural community of Upper Musquodoboit, in Halifax County. The Caribou property contains an historic gold deposit that was intermittently mined between 1869 and 1955.

The Miller Lake Project is approximately 14 kilometers from Goldenville. It has historic production and limited recent exploration. The Gold Lake Project is about 70 kilometers northeast of Halifax. It was discovered in 1867 with minor production taking place in the late 1800’s.

In November 2018, Osprey Gold provided further results from its exploration program at the Caribou Gold Project in Nova Scotia. The results provide continued evidence of lower grade disseminated mineralization within the host sediments, around the historically sampled high grade veins.

The best reported intercept was hole CM87-23 reporting 70.57 meters (m) of 1.58 grams per tonne gold (g/t Au), or 0.80 g/t Au if utilizing a 70 g/t Au grade cap. Seven holes were sampled from four key areas for a total of 395 samples submitted for analysis. Favorable initial results have led to expanded trenching and channel sampling in the Elk Zone, along strike to the east of the earlier reported trench results in ELK18-01.

Osprey Gold Development Ltd. (OSSPF), closed Friday's trading session at $0.045, up 25.00%, on 5,200 volume with 3 trades. The average volume for the last 3 months is 13,297 and the stock's 52-week low/high is $0.028/$0.093.

Magellan Gold Corp.’s primary business is the acquisition and exploration of mineral resources. The OTCQB-listed Company engages in the acquisition and exploration of precious metals mineral properties. Its updated strategic goal is building a mid-tier precious metals exploration and mining company. Magellan Gold is headquartered in Vacaville, California.

Its district-scale property position encompasses the core of the historic Silver District in La Paz County, about 50 miles north of Yuma. At the Silver District Project in southwest Arizona, the Company’s goal is to expand its resource base containing an historic resource of 16 million ounces of silver. It also plans to acquire additional advanced-stage properties that have tangible promise for development.

Magellan Gold has the right to earn an undivided 50 percent interest in the Niñobamba Silver/Gold Project in central Peru. To earn its 50 percent interest, the Company must spend $2.0 million in exploration over three years. The Niñobamba project covers 9,027 acres and demonstrates potential for a large, bulk tonnage, silver-gold deposit.

Rio Silver and its project partner, Magellan Gold, announced this past February that they initiated exploration work on the expanded Niñobamba Project. Recent strategic additions to the land package have created a large, contiguous property comprising 3100 hectares and another 553-hectare concession pending title confirmation. Magellan Gold will be spending US$2 million at the Niñobamba project to earn its 50 percent interest.

This past March, Magellan Gold announced that it entered into a Memorandum of Understanding (MOU) with Rose Petroleum plc to purchase an operating floatation plant, which also includes a precious metals leach circuit and associated assets, licenses and agreements (together, the SDA Mill), located in the State of Nayarit, Mexico, for a total consideration of US$1.5 million. The basis of the mill's normal operation is on sales of floatation concentrates to smelters, and payment for precious metals content. The mill currently engages in toll milling for third party ore producers. Rose Petroleum is a multi-asset natural resource enterprise.

This week, Magellan Gold announced it arranged $900,000 in irrevocable bridge loans in support of its option to purchase the SDA Mill from Rose Petroleum. The bridge loans are enough to complete the cash component of the purchase price and have the effect of extending the purchase option until closing of the transaction.

To extend the option, Magellan Gold had the obligation to secure the bridge loans on or before August 15, 2017. Total consideration for the purchase is US $1.5 million, comprising $1.0 million in cash and $500,000 in Magellan stock, of which $100,000 in cash already was paid.

Magellan Gold Corp. (MAGE), closed Friday's trading session at $0.027, up 2.58%, on 147,380 volume with 16 trades. The average volume for the last 3 months is 137,662 and the stock's 52-week low/high is $0.012/$0.035.

KULR Technology Group, Inc.’s mission is to utilize space technologies to make e-mobility cooler and safer. The Company’s focus is to make electronics cooler, lighter, as well as safer with carbon fiber-based thermal management technology. The Company formerly went by the name KT High-Tech Marketing, Inc. It changed its name to KULR Technology Group, Inc. in August of 2018. KULR is based in California.

KULR Technology states that its high-performance, passive thermal management technologies for electronics and energy storage applications have a unique patented carbon fiber architecture that outperforms traditional solutions. The Company is progressing towards commercializing disruptive cooling solutions on a larger scale with a primary focus on high value space, industrial, defense and electric vehicle markets. Its secondary goal is to commercialize within the consumer electronics, mobile and cloud computing markets.

KULR has an active developmental partnership with NASA (National Aeronautics and Space Administration). In addition, the Company has an exclusive license with NREL, a national laboratory of the U.S. Department of Energy. KULR also has manufacturing scalability through global partnerships.

KULR Technology Group announced in October 2018 that NASA placed an initial order for the Internal Short Circuit (ISC) trigger battery cells, which can replicate lithium-ion battery cell failures in battery pack designs. The ISC is licensed, manufactured and distributed by KULR under an exclusive agreement with the DOE’s National Renewable Energy Laboratory (NREL).

As pure carbon, KULR fiber is perfectly heat efficient. It behaves like a flexible fabric. Therefore, it can fit with just about any power or electronic configuration in extremely demanding spaces with minimal contact pressure. This can increase efficiency and safety for a variety of thermal management and energy storage uses across an array of markets.

This past November, KULR Technology Group announced that it will provide specific-use thermal management material to Leidos (LDOS) for ongoing testing, research and development on defense-related projects. Leidos is a Fortune 500® information technology, engineering, and science solutions and services leader. Leidos is working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, as well as health markets.

KULR Technology Group, Inc. (KUTG), closed Friday's trading session at $2.60, even for the day, on 2,078 volume with 7 trades. The average volume for the last 3 months is 411 and the stock's 52-week low/high is $1.10/$5.00.

Know Labs, Inc. is developing a new technology platform that measures blood glucose non-invasively. The OTCQB-listed Company invented a pioneering technology called Bio-RFID that will provide information to consumers about their health and wellness. Additionally, Know Labs utilizes its proprietary ChromaID technology to identify unique molecular signatures in materials. The Company previously went by the name Visualant, Incorporated. It changed its name to Know Labs, Inc. in May 2018. Know Labs has its corporate headquarters in Seattle, Washington.

The Company develops technology platforms that harness light and radio waves to uncover distinct insights about the world. Its technology directs electromagnetic energy through a substance or material to capture a unique molecular signature. Know Labs refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio- RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye.

ChromaID and Bio-RFID scanner modules can be integrated into an array of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests.

Know Labs announced in August 2018 its UBAND™ real time wearable calorie counter wrist band. The Calorie Counter UBAND is built upon the Company’s recent invention that detects blood glucose non-invasively. At present, Know Labs has 12 issued patents with 20 pending, covering its specialty.

Last month, Know Labs released a video highlighting its product pathway and platform. In the video, Chief Executive Officer, Mr. Phil Bosua, discusses the Company’s Bio-RFID™ technological breakthrough and the plans for bringing the technology to market.

The transcript of Mr. Bosua’s narrative in the video states in part, “We originally set out to detect blood glucose and in turn, created a platform. We’ve begun initial research to measure all types of substances in the blood and interstitial fluid. Biomarkers like cortisol for stress levels, as well as continuous measurement of the luteinizing hormone, which would indicate ovulation within the next 4 hours – ideal for those wanting to get pregnant. We’re now ahead of schedule and look forward to creating the future of non-invasive health measurements.”

Know Labs, Inc. (KNWN), closed Friday's trading session at $1.75, down 11.39%, on 56,326 volume with 107 trades. The average volume for the last 3 months is 24,775 and the stock's 52-week low/high is $0.205/$5.75.

Glance Technologies, Inc. (GLNNF)

MarketWatch, Evergreen Caller, InvestorsHub, and Emerging Growth reported on Glance Technologies, Inc. (GLNNF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Glance Technologies, Inc. owns and operates Glance Pay. This is a streamlined payment system. It transforms how smartphone users choose where to dine, order food and drink, settle bills, access digital receipts, earn excellent rewards, and interact with merchants. Regarding the Glance Pay mobile payment app, there is no set up or cancellation fees and no system integration or connections required. Glance Technologies has its corporate headquarters in Vancouver, British Columbia.

The Company is building a valuable network of merchants and consumers. Glance offers targeted in-app marketing, social media marketing, customer feedback, in-merchant messaging, as well as custom rewards programs.

The Glance Pay mobile payment system comprises proprietary technology. This technology includes user apps available for free downloads in IOS (Apple) and Android formats, a merchant manager apps, a large-scale technology hosting environment with sophisticated anti-fraud technology, and very quick payment processing.
The Glance Pay mobile payment app works for full service restaurants, quick serve, retail, and more. It also features easy activation and training and easy automatic accounting and reconciliation, and fast payment deposits. Servers and managers can review transaction details.

This week, Glance Technologies announced that it agreed to license its mobile payment technology to Active Pay Distribution, Inc. for $1,000,000. This marks Glance Technologies’ entry into the fitness hand wellness market.

With this deal, Glance Pay will create and provide the technology backbone for the Active Pay app that will serve the increasing fitness and wellness community. The app will be called Active Pay. It will be uniquely branded as Active Pay. However, it will be labeled as "powered by Glance Pay".

Additionally, merchants and users who sign up for the Active Pay app will be included in the Glance Pay app. Glance Technologies (in addition to the $1 million license fee) will receive a processing fee for transactions and a percentage of revenues generated via the Active Pay app.

Today, Glance Technologies announced that in-app digital offer concept marketing is now available to merchants and business partners. Users can redeem exclusive offers and discounts set by the retailer by way of the Company’s Deals Room directly on the Glance Pay app, lessening the need for expensive traditional paper deals, coupons, and expired email offers, while simultaneously providing creativity and flexibility for deals that are not feasible through traditional methods.

Users will continue to save time with Glance Pay by paying and leaving quicker. They now have offers to make speedier decisions on where to spend their time and money.

Glance Technologies, Inc. (GLNNF), closed Friday's trading session at $0.1332, up 21.09%, on 453,437 volume with 109 trades. The average volume for the last 3 months is 400,112 and the stock's 52-week low/high is $0.074/$1.72.

Xanthic Biopharma, Inc., together with its subsidiaries, engages in the cultivation, processing, production, distribution, and retailing of cannabis and cannabis-infused products in the United States. The Company has been operating under the trade name "Green Growth Brands" since the November 9, 2018 closing of its reverse take-over of the existing Xanthic entity. Xanthic Biopharma has its corporate headquarters in Columbus, Ohio. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Led by Mr. Peter Horvath, the Company’s team consists of retail and consumer packaged goods experts with decades of experience building successful brands. This week, Xanthic Biopharma announced that it is changing its corporate name to Green Growth Brands, Inc. The formal name change represents the next step toward the Company’s goal of becoming the premier cannabis and CBD-infused personal-care product retailer in North America.

Its brands include CAMP. This is a store for the cannabis community to find first-class products that support and enhance their active lifestyle. Brands also include Seventh Sense Botanical Therapy. This is a line of CBD infused beauty products - from body wash, lotions and balms, to hair care, lip balm and sun products. In addition, brands include Meri+Jayne that crafts and curates a mix of cannabis products.

Furthermore, Company brands include Green Lily and The Source dispensaries. The Source is the retail brand of Nevada Organic Remedies, LLC. This is a vertically integrated medical and retail marijuana company, which holds four Nevada marijuana licenses.

This week, Mr. Peter Horvath, Chief Executive Officer of Green Growth Brands, stated, "Less than two months after our RTO with Xanthic Biopharma, we are excited to be officially changing our name. 'Green Growth Brands' is reflective of the core of our business, creating exceptional experiences for consumers through our emotionally driven brands."

Xanthic Biopharma, Inc. (GGBXF), closed Friday's trading session at $3.7334, up 11.70%, on 133,703 volume with 280 trades. The average volume for the last 3 months is 150,727 and the stock's 52-week low/high is $1.8068/$4.25.

Elixinol Global Limited is a global enterprise operating in the industrial hemp, dietary supplements, and emerging medicinal cannabis sectors. The Company, by way of its businesses, has an international presence in the cannabis industry. This includes hemp-derived CBD dietary supplements, hemp food and wellness products, and the cultivation and manufacture of medicinal cannabis products. Elixinol Global is based in Sydney, Australia and the Company lists on the OTC Markets Group’s OTCQX.

Elixinol Global’s businesses include Elixinol USA, Hemp Foods Australia, and Elixinol Australia. Elixinol USA (formed in 2014) is a manufacturer and worldwide distributor of industrial hemp based dietary supplement and skincare products. Elixinol USA has operations based out of Colorado. Elixinol USA is a CBD-based dietary supplements products business. It has products presently selling in the U.S. and 40 countries.

Hemp Foods Australia (formed in 1999) is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products. Hemp Foods Australia is the largest hemp foods provider in Australia. Elixinol Australia was formed in 2014 to participate in the developing Australian medicinal cannabis market. It has applications pending for cultivation and manufacturing licenses.

This past September, Elixinol Global announced that it raised A$40m to expedite worldwide growth. Mr. Paul Benhaim, Elixinol Global Chief Executive Officer, said, “The global cannabis market is growing at a rapid rate and Elixinol Global recognizes the need to move quickly to leverage the opportunity around the business. This funding ensures we can seize the market opportunities in front of us, and in doing so, propel the business toward its next phase of growth.”

In the U.S., Elixinol Global will apply funds towards boosting the capacity of its hemp-derived CBD production facility to prepare for increasing levels of demand. Elixinol is building up its sales force and marketing efforts in the U.S. and Europe. In addition, the Company will work to build its Australian medicinal cannabis facility, upon receipt of a Medicinal Cannabis license from the Office of Drug Control.

Elixinol Global Limited (ELLXF), closed Friday's trading session at $1.9695, up 3.93%, on 314,868 volume with 199 trades. The average volume for the last 3 months is 193,585 and the stock's 52-week low/high is $0.949/$1.96.

Gilla, Inc. (GLLA)

SmallCapFinancialWire, Greenbackers, Marketbeat.com, StockBlogs, SmallCapVoice, TopPennyStockMovers, and Real Pennies reported earlier on Gilla, Inc. (GLLA), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Gilla, Inc. manufactures, markets, and distributes E-liquid (the liquid used in vaporizers, and E-cigarettes) and other vaping hardware and accessories. E-cigarettes are increasingly being considered as an alternative to conventional tobacco cigarettes. They provide authentic smoking pleasure and do not burn tobacco. Nevertheless, they are not smoking cessation devices. Gilla’s aim is to be a global leader in delivering the most efficient and effective vaping solutions for nicotine and cannabis related products. Gilla is also a developer of cannabis concentrate products.

Gilla is headquartered in Toronto, Ontario, and its manufacturing facility is in Daytona Beach, Florida. The Company has entered the cannabis industry with the introduction of its new brand of E-liquids featuring Cannabidiol (CBD). Its new brand of CBD E-liquid products will be marketed under the new label "Enriched" and www.enrichedvapor.com.

The Company is working to build and license a broad portfolio of cannabis concentrate products with a multi-jurisdictional distribution strategy, which leverages its existing sales and distribution platform along with its branding and expertise in E-liquid as a nicotine delivery solution.

Recently, Gilla announced that its Toronto-based subsidiary, Gilla Enterprises, Inc., entered into its first production and distribution licensing agreement to introduce and launch Gilla’s new portfolio of cannabis concentrate products. The Licensing Agreement was entered into with Alternative Medicine Association a Nevada-licensed medical marijuana establishment (MME) that was recently acquired by Friday Night, Inc., a Canadian-based public enterprise.

This month, Gilla announced that Gilla Enterprises closed the acquisition of all the outstanding shares of Vape Brands International, Inc., a Toronto-based manufacturer and distributor of E-liquid products, for a purchase price of up to $2,645,082. Through Vape Brands International, it acquired a state-of-the-art manufacturing facility in Toronto, six successful E-liquid brands, as well as a growing Canadian distribution network covering more than 500 retailers.

Gilla, Inc. (GLLA), closed Friday's trading session at $0.0449, up 79.60%, on 16,483 volume with 6 trades. The average volume for the last 3 months is 78,154 and the stock's 52-week low/high is $0.022/$0.21.

Aziza Project LLC

The QualityStocks Daily Newsletter would like to spotlight Aziza Project LLC.

The Aziza Project offers a tokenized oil and gas fund investment opportunity via a security token offering, which enables coin holders to share in company profits. Through its 20 percent ownership of Africa New Energies (“ANE”), the company is finding opportunity for these token holders in the underdeveloped Southern Africa region. To view the full article, visit http://ibn.fm/nUYH1.

Aziza Project LLC is a fund that tokenizes high potential oil and gas businesses in Africa, enabling them to raise funds for profit and social good. Aziza Project and its tokenization approach aims to address the obstacles associated with traditional fundraising by taking advantage of the benefits of blockchain technology to eliminate the cost and need for middlemen and complex administration. Aziza Project’s token, the Aziza Coin, is an asset-backed mid-to-long-term security token.

The vision for Aziza Project’s primary business is to light up Africa, bringing electricity to the 630 million people who currently have no access to the grid and typically depend on wood and paraffin for their energy needs, and in the process to deliver excellent returns to investors.

Through Aziza Coin, Aziza Project owns 20% of Africa New Energies (ANE), which holds rights to a 22,000-square-kilometer prospective hydrocarbon concession in Namibia. This potentially world-scale oil and gas deposit in eastern Namibia, bordering Botswana and the Kalahari Desert, could transform the region’s energy supply and provide a powerful boost to growth in Namibia. By using big data algorithms, the ANE project will be developed at a fraction of the cost of traditional methods.

In 2017 ANE rejected a $500 million unsolicited bid in the belief that this prime asset can deliver far more for investors, the local community and the people of Africa. The bid rejection has been superseded by an innovative fundraising model to unlock the value that ANE data indicates is under the ground. This sparked the genesis of Aziza Project, the creation of an oil and gas fund set up to raise capital to take ANE and other high potential oil and gas businesses to the next level smartly and efficiently.

Aziza Coins

Aziza Project is seeking to raise $60 million through the sale of Aziza Coins, an asset-backed security token compliant with the Ethereum blockchain’s ERC20 standard. The asset, a 20 percent interest in ANE, is estimated to be worth $100 million based on the value of the unsolicited bid. Funding raised by the Aziza Coin Initial Coin Offering, which began in October 2018, will be used to finance a 10 well drilling program for ANE’s Namibian concession and to develop an oil and gas fund. Proving a hydrocarbon resource will result in significant value creation for Aziza Coin holders. Proving of the project’s estimated 1.6 billion barrels of oil equivalent resource could value ANE at $3.1 billion, which would result in Aziza Project’s holding to potentially be worth up to $620 million.

The Aziza Coin seeks to create significant investor value that marries a compelling business case with the efficiency of crypto. People who buy Aziza Coins will have an indirect fractional ownership of the assets held by Aziza Project. And with tokens listed on exchanges, investors will have a degree of liquidity that private company shareholders do not have and with greater access to real returns. Aziza Coin token holders are the sole economic beneficiaries of Aziza Project’s investments and are assured that at least 51 percent of funds will be used to buy back tokens anytime a profit is made in a calendar year.

Typical investment funds charge a myriad of fees and administrative charges. These will not be present within Aziza Project LLC, with no annual fees, exit fees or salary expenses. The vision is to get as much of the investor’s dollar into the assets under management, and then on exit get as much of the asset value back to the investor. Aziza Project believes that tokenization of assets and securities is the future. Distributed ledger technology will be the catalyst for the benefit of both investors and businesses forging their way.

The Visionaries

The Aziza Coin ICO is different because its management team is very clear on valuations and laser-focused on the broader objective established by Aziza Project. The Aziza Coin is an asset-backed security token with a strong management team grounded in blue-chip corporate backgrounds and established real-world businesses.

CEO Robert Pyke has a professional background that covers consumer goods, consultancy and now cryptocurrency. Much of his career was spent at Unilever where he worked in a variety of finance roles, rising to become finance director for Unilever’s €20bn turnover Beauty and Personal Care division.

Aziza Project co-founder Shakes Motsilili has an Investments Administration background and worked for several years at Momentum Wealth as head of Actuarial Support. He resigned in 2012 to become an entrepreneur with a vision to electrify the whole of Africa.

Brendon Raw, CTO, is a South Africa-based software developer and investor in the energy technology, property and digital media sectors. Brendon was lead developer on the sales and revenue system of the one of the most valuable internet companies of its day – excite@home and was BP’s tactical application developer, creating several mission-critical commodity trading systems.

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions (OTC: SGSI), a leading telecommunications engineering and infrastructure services provider, utilizes its growth strategy which includes acquisitions and organic growth through operations. To view the full article, visit: http://nnw.fm/wT1Mb.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.

ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed the day's trading session at $0.26, up 116.67%, on 11,924 volume with 7 trades. The average volume for the last 3 months is 20,153 and the stock's 52-week low/high is $0.116/$2.59.

Sunniva, Inc. (CSE: SNN) (OTC: SNNVF)

Vertically integrated cannabis company Sunniva (CSE: SNN) (OTCQX: SNNVF) this morning announced that it has secured more than USD $2.4 million in future sales of Sunniva branded cannabis products, to be completed in the first four months of 2019. To view the full press release, visit: http://nnw.fm/Z2cjD. Also today, the company was highlighted in Venture Breakfast Bits, by 24/7 Market News. Full press release.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $3.445, up 16.78%, on 179,821 volume with 285 trades. The average volume for the last 3 months is 97,117 and the stock's 52-week low/high is $2.035/$16.00.

Canopy Rivers Inc. (TSX.V: RIV)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV).

Canopy Rivers Inc. (TSX.V: RIV) was featured today in a report by CannabisNewsWire looking at how the legalization of marijuana in Canada, and the impending legal change to marijuana laws in Mexico now leaves Texas isolated as the only jurisdiction in that area where cannabis isn’t legal. This “engulfment” is likely to generate sufficient pressure to cause a change in Texas sooner rather than later.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.

CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.

Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.

James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.

LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.

PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.

Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.

Solo Growth (TSXV:ALZ) is a premiere retail cannabis distributor that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Canada’s largest private liquor retailer, Solo Liquor, who collectively have more than 50 years of regulated substance retail experience. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy as “Solo Growth Corp.”

Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.

TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.

Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $3.50, up 4.48%, on 203,427 volume with 449 trades. The average volume for the last 3 months is 446,076 and the stock's 52-week low/high is $2.40/$11.82.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was featured today in a report by MarijuanaStox.com examining how recreational marijuana has been legal in Canada for more than two months now. However, some companies have been left in limbo, as many wait for regulations on cannabis edibles, topical's and extracts. But that's expected to change this year.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $1.95, up 1.04%, on 630,267 volume with 855 trades. The average volume for the last 3 months is 1,037,206 and the stock's 52-week low/high is $1.61/$7.89.

Green Hygienics Holdings Inc. (GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

Full-scope, premium cannabis company Green Hygienics Holdings (OTC: GRYN) is engaged in the advancement of science-driven cannabis cultivation systems with the objective of providing a premium product to the legal cannabis market. To view the full article, visit: http://nnw.fm/S8cAu.

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational market. With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company will grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions, and creating trusted global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

Hybrid-aeroponics produces quality cannabis faster than traditional methods since it doesn’t require natural sunlight or soil and can be operational and produce plants anywhere. Plants grown under aeroponic conditions receive water and nutrients directly to their roots via a fine mist in a controlled environment, dramatically reducing spoilage while keeping the product organic and the environment pest-free. The plants are given the exact amount of nutrients and moisture precisely when needed. Green Hygienics maintains ultimate control over every aspect of this cultivation process, which allows the company to operate with conservation of natural resources in mind. The technology that uses 90-95 percent less water and does not require the use of pesticides or fungicides.

Through these practices, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company continues to develop and incubate software as well as engineer hardware to provide additional control over the commercial cultivation method. The company’s science-based approach reveals any growth anomalies before the human eye can see them. This makes it possible to monitor all facets of production, identify cultivation problems based upon scientific data, and implement immediate corrective action, if needed.

The future of commercial cannabis cultivation hinges on using science to control the growing environment in order to remain competitive and deliver a premium grade of product on a consistent basis. The company holds a competitive advantage through its ability to produce premium cannabis products at a significantly lower cost per gram than direct competitors and others in the cannabis industry.

Innovations within the sector that create efficiencies and successful brands will become highly valued. Green Hygienics and its forward-thinking management team are constantly studying the market dynamics of the cannabis industry in North America and abroad while actively pursuing possible expansion opportunities. The company is headquartered in Las Vegas, Nevada and establishing operations in San Diego, California, targeting the $5 billion California cannabis market.

Green Hygienics Holdings Inc. (GRYN), closed the day's trading session at $0.37495, up 5.63%, on 701 volume with 6 trades. The average volume for the last 3 months is 13,454 and the stock's 52-week low/high is $0.026/$0.508.

Kontrol Energy Corp. (CSE: KNR) (FSE: 1K8)

The QualityStocks Daily Newsletter would like to spotlight Kontrol Energy Corp. (CSE: KNR).

The legalization of recreational cannabis on October 17, 2018, in Canada has opened a market, estimated at just under C$6 billion, to competitive forces. Now, market pressure will, undoubtedly, drive the search for more efficient production methods. One big-ticket item set to garner attention is the cost of energy, which makes up around 30 percent of direct grow expenses. This is all very well and good for Kontrol Energy Corp. (CSE: KNR) (FSE: 1K8).

Kontrol Energy Corp. (CSE: KNR) (FSE: 1K8) specializes in the integration of smart energy technologies and solutions for North American commercial and industrial property owners and operators to help them benefit from energy cost savings and minimize greenhouse gas emissions. Kontrol is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology and is ranked by Canadian Business and Maclean’s as the 7th fastest growing startup in 2018.

Kontrol’s leadership position is reshaping the way customers use, manage and strategically allocate energy resources to realize immediate energy savings by gaining more control over energy consumption and demand in real-time.

As the fastest growing global “fuel source,” energy efficiency is big business with industry analysts noting this multi-trillion-dollar market offers significant opportunities over the next five years. Established market segments include: energy retrofits ($71.4 billion); distributed generation ($179.9 billion); energy analytics ($33.5 billion); and greenhouse gas/carbon measurement, reduction ($1.2 trillion). Each $1 invested in energy efficiency displaces up to $3 of utility-scale transmission and distribution investment, according to the International Energy Agency.

Formed in 2015 by a group of energy veterans who recognized that the energy efficiency industry is one of the fastest growing fuel sources for the global economy, Kontrol is committed to enhancing and improving its customers sustainability objectives. In less than two years, Kontrol has grown its revenue run rate to $16 million from $1.8 million, delivering on stated goals and objectives as it seeks to continue this pattern through accretive acquisitions and the expansion of the company’s smart energy technologies.

Up to 50 percent of Kontrol’s overall revenues are recurring annually, and the company’s 2019 outlook includes strategic initiatives that will expand the company’s smart energy technologies to U.S. markets, bring additional accretive and strategic acquisitions, and accelerate recurring SaaS revenues.

Kontrol’s strategy of disciplined mergers and acquisitions includes the following highlights:

Acquisition of Log-One Ltd.’s award-winning energy conservation technology, Energy Management System (“EMS”), an intelligent, occupancy-based heating and air-conditioning control system for commercial and multi-residential real estate. Rebranded as Kontrol EMS Technology, the company has added IoT and mobile application capabilities, creating a recurring revenue platform through a Software-as-a-Service (SaaS) platform.

Acquisition of MCW Dimax Ltd. (“MCX”), a firm specializing in solutions for the application of energy software to analyze the management of complex heating, ventilation and cooling systems for large residential, commercial, and mission critical real estate owners.

The company has also established entry into the North American cannabis market as a supplier of integrated energy efficiency solutions and technologies. Within this market, Kontrol is focused on assisting cannabis growers to reduce the cost of energy and support mission critical infrastructures. To date, Kontrol has secured two contracts to provide energy efficiency services with Licensed Producers in the Canadian cannabis sector.

The Kontrol Energy group of companies is currently saving its customers more than 40 million kilowatt hours of electricity per annum and providing a corresponding reduction in GHG emissions.

Kontrol’s management team includes CEO Paul Ghezzi, a leader in clean tech, renewable energy development, solar project financing and distributed generation. Ghezzi has global experience in power generation projects under Feed-in Tariff programs and Power Purchase Agreement programs for both commercial and utility-scale projects. COO Kristian Lavereau has more than 25 years of experience in the IT solutions (analytics and mobile computing), energy optimization and efficiency (intelligent control systems, solar PV, lighting). Claudio Del Vasto, CPA, CA | CFO, is a senior finance executive with an extensive background in corporate finance, strategy and business development.

Kontrol Energy Corp. (CSE: KNR), closed the day's trading session at $0.65, up 3.17%, on 3,000 volume with 5 trades. The average volume for the last 3 months is 19,343 and the stock's 52-week low/high is $0.46/$1.58.

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com (OTCQB: CIIX), developer of a proprietary financial news media and content platform providing information to the global Chinese-speaking community, recently announced the execution of a letter of intent (“LOI”) to acquire exclusive rights to all sales channels for the VitaMist product line in Asian markets domestically and internationally. To view the full article, visit: http://nnw.fm/2I8gv. Also today, NetworkNewsWire released a report on the company detailing how CIIX recently announced (http://nnw.fm/RKxr6) that it has retained Boustead Securities, LLC for the underwriting of the planned initial public offering (IPO) of its wholly owned foreign enterprise, CBD Biotech Co. Ltd.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.508, up 3.67%, on 126,458 volume with 61 trades. The average volume for the last 3 months is 284,543 and the stock's 52-week low/high is $0.365/$1.25.

CytoDyn Inc. (CYDY)

Biotechnology company CytoDyn (OTCQB: CYDY) anticipates that it will attain final FDA approval for its HIV treatment, PRO 140, by the fourth quarter of 2019. The company expects market availability will follow by 2020. To view the full article, visit: http://nnw.fm/zWs5K.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.5445, up 2.90%, on 141,136 volume with 40 trades. The average volume for the last 3 months is 188,417 and the stock's 52-week low/high is $0.40/$0.836.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital Corp. (CSE: CALI) (OTC: FNNZF) a royalty company for the U.S. licensed medical cannabis industry announces its intention to raise CAD$1.5 million by way of Secured Convertible Debentures (“Debentures”). The Debentures will be secured by a general security interest, will mature two years from closing and will bear interest at 12% per annum, payable in cash or, at the option of the Subscriber, in common shares of FinCanna ("Common Shares") subject to certain conditions.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.087, up 10.97%, on 80,053 volume with 9 trades. The average volume for the last 3 months is 52,093 and the stock's 52-week low/high is $0.0577/$0.8736.

Icon Exploration Inc. (TSX.V: IEX.H)

New job and wage statistics released just shy of Canada’s two-month anniversary for full-use cannabis legalization underscore the strength of the ‘weed’ industry, as well as the market potential of companies such as Icon Exploration Inc. (TSX.V: IEX.H) that are aiming to build the industry into a multi-billion-dollar juggernaut.

Icon Exploration Inc.'s (TSX.V: IEX.H) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

Icon Exploration Inc. (TSX.V: IEX.H), closed the day's trading session at $0.41, even for the day. The stock's 52-week low/high is $0.25/$0.84.

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures (OTC: NUGS) operates through the acquisition and development of companies within the cannabis and ancillary sectors that are in startup and growth stages. The legal cannabis industry is positioned for substantial growth, according to Forbes (http://nnw.fm/1LpqE). To view the full article, visit: http://nnw.fm/nXm08. Also today, the company was featured today in a report by CannabisNewsWire looking at how the legalization of marijuana in Canada, and the impending legal change to marijuana laws in Mexico now leaves Texas isolated as the only jurisdiction in that area where cannabis isn’t legal. This “engulfment” is likely to generate sufficient pressure to cause a change in Texas sooner rather than later.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $1.81, off by 1.63%, on 98,188 volume with 128 trades. The average volume for the last 3 months is 45,196 and the stock's 52-week low/high is $1.02/$5.94.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Biotechnology company and drug delivery platform innovator Lexaria Bioscience recently put its aggressive growth strategy into effect with the additions of a new corporate controller, a head of its legal division and more office staff. The company also intends to increase its lab personnel in 2019. A recent article further discussing the company reads, “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, has announced aggressive growth plans, including the addition of key personnel, a special focus on its lab R&D activities in 2019 and the issue of new stock options. To view the full article, visit: http://nnw.fm/AbbY3.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.00, off by 1.96%, on 226,641 volume with 175 trades. The average volume for the last 3 months is 185,820 and the stock's 52-week low/high is $0.75/$2.43.

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Leading omni-direct lifestyle company Youngevity International (NASDAQ: YGYI) employs a fusion of the direct selling business model, offering products in the health and nutrition, home and family, food and beverage, spa and beauty, fashion, essential oils, photo and innovative services categories. To view the full article, visit: http://nnw.fm/E7W7f.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

Health and Nutrition

Home and Family

Food and Beverage

Spa and Beauty

Fashion

Essential Oils

Photo and scrapbooking

Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $5.17, off by 7.84%, on 83,471 volume with 468 trades. The average volume for the last 3 months is 558,498 and the stock's 52-week low/high is $3.167/$16.25.

The QualityStocks DailyNetwork Sponsors

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.